KBRA Issues Ratings for Orange County Bancorp, Inc.
Credit Ratings Assigned: KBRA has assigned various credit ratings to Orange County Bancorp, Inc. and its subsidiary, Orange Bank & Trust Company, with long-term ratings of BBB and BBB+, respectively, and a Stable Outlook for all ratings.
Strong Deposit Franchise: The bank's ratings are bolstered by its low deposit costs, conservative liquidity management, and a strong core deposit base, which supports solid profitability and a favorable net interest margin (NIM).
Credit Quality and Risk Management: While the bank has reported some elevated non-performing loans, its core portfolio remains strong, and management's disciplined approach to lending helps mitigate concentration risks.
Capital Strength and Growth Strategy: The bank has strengthened its capital ratios through a recent equity raise and plans to focus on organic growth, with the flexibility for opportunistic M&A if strategically beneficial.
Trade with 70% Backtested Accuracy
Analyst Views on OBT
About OBT
About the author
Oxford BioTherapeutics Partners with GSK to Advance Novel Cancer Therapies
- Strategic Collaboration: Oxford BioTherapeutics (OBT) has entered a multi-year strategic collaboration with GSK to leverage OBT's OGAP®-Verify platform for identifying multiple novel oncology targets, aiming to develop first-in-class antibody-based cancer therapeutics, showcasing OBT's strong potential in oncology innovation.
- Financial Support: Under the agreement, OBT will receive an undisclosed upfront payment from GSK and may be eligible for downstream milestone payments and royalties on net sales, providing crucial funding to support OBT's research and development pipeline.
- Technological Advantage: OBT's OGAP®-Verify platform enhances target identification sensitivity and specificity, supporting the development of differentiated antibody-based therapies, which not only boosts OBT's R&D capabilities but may also accelerate the time-to-market for new drugs, addressing unmet patient needs.
- Market Outlook: This collaboration marks OBT's second major partnership with a leading global pharmaceutical company this year, reflecting its growing influence in cancer research and is expected to enhance OBT's competitiveness and market share in the global biopharmaceutical landscape.
Daily Upgrade Report for Validea's John Neff Strategy - December 2, 2025
Validea's Low PE Investor Model: Today's upgrades for Validea's Low PE Investor model, based on John Neff's strategy, highlight several stocks with improved ratings due to strong fundamentals and valuations, including Edison International, Mercantile Bank Corp, and others.
Edison International (EIX): This large-cap value stock in the Electric Utilities industry saw its rating increase from 58% to 77%, indicating growing interest based on its fundamentals and valuation.
Mercantile Bank Corp (MBWM): A small-cap value stock in the Money Center Banks industry, its rating improved from 60% to 79%, reflecting positive changes in its underlying fundamentals and stock valuation.
Asbury Automotive Group Inc (ABG): This mid-cap value stock in the Retail (Specialty) industry also experienced a rating increase from 62% to 81%, suggesting strong interest based on its financial performance and valuation metrics.
